New RESPOND Trial Targets Depression Linked to Early Life Adversity and Hormonal Sensitivity

Depression that follows childhood trauma has long frustrated clinicians, because it rarely behaves like the textbook illness described in diagnostic manuals. A newly published study protocol in BMC Psychiatry describes an ambitious attempt to change that: the RESPOND trial, a single-arm, open-label, proof-of-concept study designed specifically for individuals assigned female at birth who carry both a history of early life adversity and depressive symptoms shaped by hormonal sensitivity. The trial, led by Katerina Dikaios and colleagues at St. Joseph’s Healthcare Hamilton and McMaster University, pairs a novel twelve-week psychotherapy protocol with an integrated neurobiological investigation that spans inflammation, DNA methylation, and neurosteroids. Registered on ClinicalTrials.gov under identifier NCT07250893 and approved by the Hamilton Integrated Research Ethics Board, the study represents a rare convergence of psychotherapy innovation and molecular psychiatry aimed at a population that the researchers argue has been systematically underrepresented in both trauma and mood disorder research.

The scientific rationale rests on one of the most robust findings in psychiatric epidemiology: exposure to early life adversity is a powerful predictor of later psychiatric illness. But the RESPOND team goes further, focusing on a mechanism that has received comparatively little clinical attention. In individuals assigned female at birth, early adversity appears to alter neuroendocrine, epigenetic, and inflammatory processes in ways that heighten sensitivity to reproductive hormonal transitions throughout life, including the menstrual cycle, the postpartum period, and menopause. The result is a clinical profile the investigators call hormonal sensitivity, in which psychiatric symptoms flare and recede in cyclical patterns tied to shifting physiology. Crucially, these patients often present with symptom pictures that fall outside traditional diagnostic boundaries, meaning they may not qualify cleanly for existing trauma-focused or mood-focused treatments, and no psychotherapy protocol has previously been designed to address the three-way interaction between early adversity, hormonal sensitivity, and depression.

The intervention at the heart of the trial is deliberately hybrid in design. Rather than inventing a therapy from scratch, the researchers integrate components from three well-established modalities: cognitive behavioural therapy, which targets maladaptive thought patterns and behaviour; dialectical behaviour therapy, which builds skills for tolerating distress and regulating intense emotion; and cognitive processing therapy, which addresses the distorted beliefs about self and world that trauma implants. Delivered entirely virtually over twelve weeks, the phase-based structure allows the treatment to unfold in stages, an architecture the investigators chose to match the layered needs of people whose depression is entangled with developmental trauma and fluctuating hormonal states. The virtual delivery model also broadens access, a practical consideration for a population that often faces barriers to specialized in-person care.

Forty participants will complete the intervention, and the trial will track them at four time points: baseline, mid-treatment, post-treatment, and a three-month follow-up. The primary outcome is change in depressive symptoms measured with the Quick Inventory of Depressive Symptoms, a validated instrument widely used in clinical trials because of its sensitivity to change. Secondary outcomes extend the lens beyond mood, capturing emotional regulation with the Difficulties in Emotional Regulation Scale, trauma symptoms with the PTSD Checklist for the DSM-5, and day-to-day functioning with the Illness Intrusiveness Scale. Resilience will also be gauged using the Connor Davidson Resiliency Scale, and trauma history will be assessed with instruments including the Childhood Experiences of Care and Abuse measure and the International Trauma Questionnaire, which allows for diagnoses of complex posttraumatic stress disorder and disturbances in self-organization that standard checklists often miss.

What distinguishes RESPOND from most psychotherapy trials is its insistence on measuring the biology that accompanies symptom change. Hormonal sensitivity itself will be quantified through daily symptom charting, including the McMaster Premenstrual and Mood Symptom Scale developed by the senior author’s group and the Greene Climacteric Scale for menopausal symptoms, allowing the team to map symptom cycles against each participant’s reproductive stage. Blood-based biomarkers will be collected before and after treatment, targeting three biological systems implicated in the aftermath of early adversity. Inflammatory markers, including C-reactive protein, interleukin-6, interleukin-10, and tumor necrosis factor-alpha, will index the chronic low-grade inflammation that childhood trauma leaves in its wake. DNA methylation patterns will probe the epigenetic scars that adversity imprints on gene expression. And neurosteroids, including allopregnanolone, the progesterone metabolite that powerfully modulates GABA receptors in the brain, will illuminate the endocrine machinery most directly tied to hormonal sensitivity.

The neurosteroid angle is scientifically compelling because allopregnanolone sits at the crossroads of the trial’s central hypothesis. This metabolite fluctuates naturally across the menstrual cycle, pregnancy, and menopause, and it acts on gamma-aminobutyric acid receptors, the same targets engaged by sedative drugs and, more recently, by approved treatments for postpartum depression. Enzymes such as 3-alpha-hydroxysteroid dehydrogenase, 3-beta-hydroxysteroid dehydrogenase, 5-alpha-reductase type 1, and 5-beta-reductase govern its synthesis and metabolism, and early life adversity is thought to dysregulate these pathways. By measuring neurosteroids alongside inflammatory and epigenetic markers before and after psychotherapy, the investigators can ask a genuinely novel question: whether a targeted psychological intervention can shift not only how patients feel but also the measurable physiological signals that early adversity has written into their bodies.

The study’s analytical framework reflects its proof-of-concept ambitions. Because the trial lacks a control arm, it cannot definitively attribute improvement to the therapy itself; instead, it is designed to establish feasibility, acceptability, and preliminary signal. Linear mixed-effects models will handle the repeated measurements over time, and intraclass correlations will quantify reliability of the assessments. This is the standard architecture of an early-phase behavioural trial, and the team is explicit that the goal is to characterize biological mechanisms shared between early adversity and mood disturbance while assessing whether targeted psychotherapy can move both clinical symptoms and biological markers in parallel. If the signal is strong, the foundation exists for larger randomized controlled trials, and the biomarker data could eventually help identify which patients are most likely to benefit, a step toward precision mental health.

For the population the trial serves, the stakes are considerable. Individuals assigned female at birth with complex depression related to early life adversity frequently cycle through treatments designed for prototypical major depressive disorder or single-event PTSD, and find partial relief at best. Their symptoms may intensify predictably before menstruation, after childbirth, or during the menopausal transition, patterns that mainstream diagnostic frameworks have historically treated as separate conditions or dismissed entirely. The RESPOND investigators frame their work as an attempt to correct that exclusion, building a treatment and a research program around the actual clinical needs of these patients rather than forcing them into categories that were never designed for them. The involvement of the Women’s Health Concerns Clinic and the Anxiety Treatment and Research Clinic at St. Joseph’s Healthcare Hamilton underscores the translational intent of the project.

The trial’s practical details signal careful attention to modern research standards. All data will be managed through REDCap, the widely used research electronic data capture platform, with compliance frameworks including HIPAA and FISMA referenced in the protocol’s security posture. Funding comes from an unrestricted educational donation from SunLife Canada, with the protocol itself not peer reviewed by the funder, and the authors declare no competing interests. Diagnostic characterization will rely on the Diagnostic Assessment and Research Tool alongside the Montgomery Åsberg Depression Rating Scale as a clinician-rated complement to self-report measures. With the record first released in August 2025 and updated through July 2026, and the protocol published open access on 17 September 2026, the RESPOND trial now moves from design to evidence generation, and its results could reshape how clinicians conceptualize and treat the depression that so often follows childhood adversity in hormonally sensitive patients.

Subject of Research: A phase-based psychotherapy protocol with integrated neurobiological investigation for depression following early life adversity in hormonally sensitive individuals

Article Title: The RESPOND trial: protocol for a novel phase-based psychotherapy and integrated neurobiological investigation of depression following early life adversity

Article References: Dikaios, K., Green, S. M., Ramos-Lima, L. F., Boyd, J., & Frey, B. N. (2026). The RESPOND trial: protocol for a novel phase-based psychotherapy and integrated neurobiological investigation of depression following early life adversity. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08586-w

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08586-w

Keywords: early life adversity, depression, hormonal sensitivity, psychotherapy, RESPOND trial, neurosteroids, allopregnanolone, inflammation, DNA methylation, women's mental health, trauma, emotional dysregulation